Posted by Michael Wonder on 20 Jul 2021
Almirall receives European Commission approval of Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis
19 July 2021 - Klisyri (tirbanibulin) is a topical first in class microtubule inhibitor indicated for the treatment of actinic keratosis of the face or scalp in adults and it acts through a selective anti-proliferative mechanism of action.
Almirall announced today that the European Commission has approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis on the face or scalp in adults.
